{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:46:20Z","timestamp":1786373180952,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Kidney transplantation is the preferred treatment for patients with ESRD. It improves the quality of life in recipients, increases patient survival, and is also substantially less costly than maintenance dialysis. Long-term transplant success requires immunosuppressant drug therapy for the life of the allograft. Under current law, Medicare coverage for most recipients (except for those recipients over 65 years of age or with nonkidney-related disabilities) lasts only 3 years, leaving many recipients unable to afford these medications. Lack of drug therapy often leads to allograft rejection, resulting in premature graft failure, return to dialysis, or death. This article reviews the current policy for Medicare immunosuppressive drug coverage and analyzes the potential impact of pending legislative proposals H.R. 2969 and S. 1454 and the Patient Protection and Affordable Care Act.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.09440912","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T23:53:49Z","timestamp":1365119629000},"page":"1258-1266","source":"Crossref","is-referenced-by-count":31,"title":["Future of Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the United States"],"prefix":"10.2215","volume":"8","author":[{"given":"Bekir","family":"Tanriover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20230811","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1523-1755.2001.00961.x","article-title":"The natural history of azathioprine compliance after renal transplantation","volume":"60","author":"Nevins","year":"2001","journal-title":"Kidney Int"},{"key":"R2-28-20230811","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellares","year":"2012","journal-title":"Am J Transplant"},{"key":"R3-28-20230811","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0272-6386(12)80713-X","article-title":"Tapering or discontinuing cyclosporine for financial reasons\u2014a single-center experience","volume":"21","author":"Sanders","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"R4-28-20230811","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00007890-199502000-00006","article-title":"Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients","volume":"59","author":"De Geest","year":"1995","journal-title":"Transplantation"},{"key":"R5-28-20230811","first-page":"63","article-title":"Patient noncompliance: A major cause of late graft failure in cyclosporine-treated renal transplants","volume":"20","author":"Didlake","year":"1988","journal-title":"Transplant Proc"},{"key":"R6-28-20230811","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2165\/00003495-200262040-00002","article-title":"Issues of adherence to immunosuppressant therapy after solid-organ transplantation","volume":"62","author":"Chisholm","year":"2002","journal-title":"Drugs"},{"key":"R7-28-20230811","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1016\/S0041-1345(99)00114-1","article-title":"Nonadherence to immunosuppressive medications: A pilot survey of members of the transplant recipients international organization","volume":"31","author":"Kory","year":"1999","journal-title":"Transplant Proc"},{"key":"R8-28-20230811","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.2105\/AJPH.92.7.1120","article-title":"Prescription noncompliance due to cost among adults with disabilities in the United States","volume":"92","author":"Kennedy","year":"2002","journal-title":"Am J Public Health"},{"key":"R9-28-20230811","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/S0041-1345(99)00118-9","article-title":"Late renal allograft loss: noncompliance masquerading as chronic rejection","volume":"31","author":"Gaston","year":"1999","journal-title":"Transplant Proc"},{"key":"R10-28-20230811","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJMp1114394","article-title":"Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation","volume":"366","author":"Gill","year":"2012","journal-title":"N Engl J Med"},{"key":"R16-28-20230811","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2215\/CJN.02430607","article-title":"Medicare from A to D: What every nephrologist needs to know","volume":"3","author":"Morrison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R18-28-20230811","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1016\/S0041-1345(99)00121-9","article-title":"A medical anthropologist\u2019s view on posttransplant compliance: The underground economy of medical survival","volume":"31","author":"Sharp","year":"1999","journal-title":"Transplant Proc"},{"key":"R19-28-20230811","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1525\/maq.1995.9.3.02a00050","article-title":"Organ transplantation as a transformative experience: Anthropological insights into the restructuring of the self","volume":"9","author":"Sharp","year":"1995","journal-title":"Med Anthropol Q"},{"key":"R21-28-20230811","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.TP.0000162980.68628.5A","article-title":"A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients","volume":"80","author":"Hardinger","year":"2005","journal-title":"Transplantation"},{"key":"R22-28-20230811","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2215\/CJN.04220510","article-title":"Cost-related immunosuppressive medication nonadherence among kidney transplant recipients","volume":"5","author":"Evans","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-28-20230811","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1399-0012.2008.00869.x","article-title":"The financial impact of immunosuppressant expenses on new kidney transplant recipients","volume":"22","author":"Gordon","year":"2008","journal-title":"Clin Transplant"},{"key":"R24-28-20230811","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1034\/j.1600-6143.2001.010113.x","article-title":"Effect of extended coverage of immunosuppressive medications by medicare on the survival of cadaveric renal transplants","volume":"1","author":"Woodward","year":"2001","journal-title":"Am J Transplant"},{"key":"R28-28-20230811","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1600-6143.2004.00565.x","article-title":"Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant","volume":"4","author":"Yen","year":"2004","journal-title":"Am J Transplant"},{"key":"R29-28-20230811","first-page":"95","article-title":"Cost of lifetime immunosuppression coverage for kidney transplant recipients","volume":"30","author":"Page","year":"2008","journal-title":"Health Care Financ Rev"},{"key":"R31-28-20230811","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/j.1600-6143.2010.03246.x","article-title":"US Health Care Reform and Transplantation. Part I: Overview and impact on access and reimbursement in the private sector","volume":"10","author":"Axelrod","year":"2010","journal-title":"Am J Transplant"},{"key":"R32-28-20230811","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2215\/CJN.02610310","article-title":"A conflict of responsibility: No patient left behind","volume":"5","author":"Becker","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R33-28-20230811","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2215\/CJN.01630210","article-title":"Drug coverage for transplantation turns into political football: Big business trumps patients","volume":"5","author":"Cohen","year":"2010","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201307000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:14Z","timestamp":1786369394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201307000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09440912","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}